Watch DWTX. Know when insiders buy.
One email the day a filing lands. Free.
DWTX
Dogwood Therapeutics, Inc.
1.94
+0.06 +3.19%
USD · close Sep 11
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
100
PASS · shorts 100
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $65.9MP/E 0.9DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$36MNET CASH —52W 1.34 – 7.91SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$14.1M | −$11.5M | — | -0.34 | −$3.6M | — | — | Aug 14 |
| Q1 2026 · Mar 31 | — | — | — | −$5.1M | −$5M | — | -0.15 | −$4.6M | — | — | Aug 14 |
| Q4 2025 · Dec 31derived | — | — | — | −$3.8M | −$3.8M | — | 10.89 | −$3.6M | — | — | Mar 18 |
| Q3 2025 · Sep 30 | — | — | — | −$15.8M | −$15.7M | — | -8.20 | −$3.3M | — | — | Nov 7 |
| Q2 2025 · Jun 30 | — | — | — | −$3.9M | −$3.8M | — | -1.99 | −$4M | — | — | Aug 14 |
| Q1 2025 · Mar 31 | — | — | — | −$4.4M | −$10.9M | — | -8.45 | −$4.7M | — | — | Aug 14 |
| Q4 2024 · Dec 31derived | — | — | — | −$7.5M | −$7.7M | — | -7.57 | −$6.1M | — | — | Mar 18 |
| Q3 2024 · Sep 30 | — | — | — | −$2.3M | −$2.3M | — | -2.05 | −$910K | — | — | Nov 7 |
| Q2 2024 · Jun 30 | — | — | — | −$1.1M | −$1M | — | -1.15 | −$812K | — | — | Nov 7 |
| Q1 2024 · Mar 31 | — | — | — | −$1.3M | −$1.3M | — | -1.68 | −$937K | — | — | Nov 7 |
| Q4 2023 · Dec 31derived | — | — | — | −$1.1M | −$1.1M | — | -1.42 | −$1.5M | — | — | Mar 31 |
| Q3 2023 · Sep 30 | — | — | — | −$1.3M | −$1.2M | — | -1.62 | −$960K | — | — | Nov 8 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$28M | −$34.3M | — | -7.13 | −$15.6M | — | — | — | — |
| FY2024 · to Dec 31 | — | — | −$12.2M | −$12.3M | — | -12.52 | −$8.8M | — | — | — | — |
| FY2023 · to Dec 31 | — | — | −$5.4M | −$5.3M | — | -7.05 | −$4.9M | — | — | — | — |
| FY2022 · to Dec 31 | — | — | −$12.3M | −$12.2M | — | -1.11 | −$11.5M | — | — | — | — |
| FY2021 · to Dec 31 | — | — | −$15.6M | −$16M | — | -1.92 | −$15.7M | — | — | — | — |
| FY2020 · to Dec 31 | — | — | −$10M | −$10.3M | — | -2.10 | −$3.9M | — | — | — | — |
Every number comes from Dogwood Therapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.